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Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic 
liver diseases with 10–30% prevalence in western countries. The severity of NAFLD 
ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepa-
tocellular carcinoma (HCC). However, the wide range of clinical staging of the disease 
prevents the clear understanding of its pathogenesis. Recently, high-throughput genomic, 
transcriptomic, and proteomic studies focus on enlightening the complex mechanisms 
responsible for NAFLD and NASH development. All together these Omics studies, in dif-
ferent cohorts once again, proved that NAFLD and NASH are linked with many complex 
mechanisms such as accumulation and traffic of various lipids in the liver and activation 
of inflammation responses. Moreover, some of these studies may have identified potential 
biomarkers and candidate risky or protective alleles that can be a valuable tool for the 
assessment of susceptibility and histological severity of NAFLD. Nonetheless, confirma-
tion of these potential biomarkers and candidate genes by multiple Omics tools is required 
for their clinical application in the diagnosis and treatment of NASH and NAFLD.
Keywords: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver, 
genomics, proteomics, Omics, GWAS, NASH, NAFLD
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is a serious hepatic disorder, affecting up to 30% 
of the general population of Western countries and approximately 15% in Asian population 
[1, 2]. The increased prevalence in developing countries is related with sedentary life style and 
lack of exercise. Moreover, the increase in NAFLD prevalence is also related with alterations 
in dietary intake caused by urban lifestyle which is represented by a 24% augmented energy 
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intake because of the enhancements in the consumption of flour, cereal products, and added 
sugar and fats and/or in total fat and fruit intake [3]. In addition, the use of corn syrup or 
high fructose as sweeteners in beverages greatly contributed the prevalence of NAFLD [4]. 
Hence, various dietary models are being evaluated for prevention of NAFLD. The top studied 
dietary interventions include diets restricted in calories and carbohydrates with soy protein 
addition, low calorie diet rich in proteins, high protein diet, soft drinks with fructose com-
pared to glucose sodas, and Mediterranean diet [5]. The fact that NAFLD is the second most 
common reason for liver transplantation emphasizes the burden of NAFLD to public health 
[6]. NAFLD comprises an entire pathological spectrum of diseases with successive stages of 
increasing severity, ranging from simple steatosis (SS), non-alcoholic steatohepatitis (NASH), 
and cirrhosis to hepatocellular carcinoma (HCC) [7]. The end result, HCC, is the fifth com-
mon cancer among all primary neoplastic diseases and affects one million individuals annu-
ally worldwide. Despite the common fact that hepatitis B or hepatitis C infection-associated 
liver cirrhosis or abusive alcohol consumption is the primary cause of HCC, recent studies 
reported that HCCs may also affect non-cirrhotic livers, most of them having no associated 
risk factors. Consequently, NASH is now evaluated as a significant risk factor due to the high 
prevalence of obesity and type 2 diabetes mellitus [8]. Recent reports stated that the risk to 
develop HCC in patients with metabolic syndrome is increased by 2.13 (odd ratio), while the 
increase rate is 4.4 in patients with NAFLD [9, 10].
NAFLD is closely associated with obesity, combined hyperlipidemia, type II diabetes mel-
litus, high blood pressure, and insulin resistance; it can be regarded as the hepatic manifes-
tation of metabolic syndrome [11]. Insulin resistance, dyslipidemia, and cardiovascular risk 
factors are known to arise from abnormalities in fatty acid metabolism and systemic inflam-
mation, but the exact link between metabolic syndrome and the onset and progression of 
liver injury is still unclear [12]. Steatosis, characterized by an accumulation of triglycerides in 
the liver parenchyma, may develop into NAFLD if the rates of hepatic uptake of circulating 
blood free fatty acids (FFA), which originates from excessive adipose tissue lipolysis, and de 
novo liver lipogenesis from glucose are greater than the rate of mitochondrial fatty acid oxida-
tion or export as triglycerides within low-density lipoproteins. This phenomenon arises from 
abnormalities in glucose, fatty acid, and lipoprotein metabolism accompanied by the develop-
ment of insulin resistance. On the other hand, upcoming evidence now suggest that triglycer-
ide accumulation in the form of lipid droplets could instead be a parameter of excessive fatty 
acid trafficking, while non-triglyceride fatty acid metabolites would be the consequence of 
lipotoxicity of the NASH pathogenesis [13]. Insulin resistance results in an excessive flow of 
fatty acids from the adipose tissue and also hinders peripheral glucose removal. In the liver, 
fatty acid disposal causes excessive production of reactive oxygen species, followed by lipid 
peroxidation and augmented inflammatory response [14]. Still, the exact mechanism that 
explains progression of SS to NASH is not yet fully clear. Currently, liver biopsy is still the 
gold standard in diagnosis of NAFLD. The histological indication of NAFLD is determined as 
lipid accumulation in the hepatocytes in the absence of pathologies such as viral hepatitis or 
alcohol abuse [15]. However, liver biopsy has certain disadvantages. First and most important 
of all, it is an invasive procedure. Moreover, since NAFLD does not uniformly affect liver, this 
heterogeneity may cause some biases in biopsy results [16, 17]. Hence, there is an urgent need 
for non-invasive biomarkers to assess liver diseases such as NAFLD.
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Currently, high-throughput Omics studies engage in to solve the complex mechanisms 
responsible for NAFLD and NASH development. The genomic studies focus on genome-
wide association studies (GWAS) that identify biomarkers across whole genomes to determine 
genetic variations associated with a disease of interest. The technologies of high-throughput 
genotyping are now able to assay the common single nucleotide polymorphism (SNP) and 
find the association between SNPs and clinical conditions or measurable traits [18]. As in 
many other diseases, besides genetic factors epigenetics and transcriptomic alterations are 
involved in the development of NAFLD and NASH. Additionally, identification of specific 
proteins, either as novel biomarkers or as over-/under-expressed markers through proteomic 
studies, may have a massive effect by increasing the availability of biomarkers for early diag-
nosis and therapy [19].
The development of NAFLD is a complex multifactorial process that involves the disrup-
tion of multiple gene and protein mechanisms. Initially, Day and James suggested a “two-hit 
hypothesis” to define the development of NAFLD: The “first hit” corresponds to a primary 
hepatic lipid accumulation which is described as steatosis; the “second hit” is an oxidative 
stress leading to lipid peroxidation, followed by liver injury and inflammation [20]. Recently, 
this traditional “two-hit hypothesis” has been upgraded to “multiple parallel hits hypoth-
esis.” It has been proposed that significant overlaps among insulin resistance, hepatic de novo 
lipogenesis, and subsequent hepatocyte injury also come into play in the progression from 
SS to NASH [21]. In addition, various candidate gene studies focusing on genetic factors of 
NAFLD development have further supported the “multiple parallel hits hypothesis” [22]. 
This review aims to sum up the current Omics studies such as genomics, transcriptomics, and 
proteomics to offer a better understanding of the pathogenesis of NAFLD.
2. Genomics in NAFLD
Accomplishment of Human Genome Project in 2003 greatly accelerates genome-wide associa-
tion studies (GWAS) that enable researchers to identify biomarkers across genomes of popu-
lation that are associated with a given disease. GWAS has a unique hypothesis-free approach 
that comes handy for examining genes that otherwise would have not been considered as 
candidates because of our limited knowledge of their function and for revealing as well non-
protein coding regions of the genome that involve crucial regulatory alterations [14]. Thus, 
there are multiple GWAS conducted to identify genes that are associated with the develop-
ment of NAFLD. According to genomic studies, the associated genes with the pathophysi-
ology of NAFLD belong to hepatic lipid metabolism, ECM balance, cytokines, and insulin 
resistance [11] (Table 1).
The first GWA study that was performed by Romeo et al. notably increased the notion that 
genetic factors could affect the susceptibility of NAFLD [24]. In their study, Romeo et al. 
presented the association between a genome-wide survey of 9229 non-synonymous SNPs 
and hepatic fat detected by MR spectroscopy in 1032 African-American, 696 European-
American, and 383 Hispanic adults residing in Dallas County and found that an allele in 
human patatin-like phospholipase domain containing 3 gene (PNPLA3) (rs738409, I148M) 
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was strongly contributing increased hepatic lipid levels, alanine aminotransferase levels, 
and hepatic inflammation. PNPLA3 gene that encodes adiponutrin is known to have lipase 
activity in vitro and has been shown to be involved in glucose and lipid metabolism [24]. 
Recent reports also supported the importance of this variant in NASH progression owing to 
its connection with fibrosis development [25]. The association of this variant in PNPLA3 gene 
(rs738409; I148M) with the susceptibility and histological severity of NAFLD was also con-
firmed by the study of Sookoian and Pirola which included 2937 subjects [26]. Chalasani et al. 
have examined 324,623 SNPs from the 22 autosomal chromosomes in 236 non-Hispanic white 
women with well-diagnosed NAFLD for their clinical and histological features [27]. They 
reported association of SNP rs2645424 on chromosome 8 in farnesyl diphosphate farnesyl 
transferase 1 (FDFT1) with NAFLD activity score and SNP rs1227756 on chromosome 10 in a 
collagen XIII variant (COL13A1), with lobular inflammation. While they stated association of 
several variants with the degree of fibrosis or serum levels of alanine aminotransferase, they 
found no significant association between genotypes and steatosis, ballooning degeneration, 
portal inflammation, or other features of NAFLD. Transmembrane 6 Superfamily Member 2 
(TM6SF2) gene is also found to be associated with NAFLD [30]. Minor allele frequency for the 
rs58542926 TM6SF2 polymorphism has been reported as 7% in Europeans, 4% in Hispanics, 
and 2% in African Americans [31], which are much lesser than MAF for PNPLA3 rs738409 
(I148M) variant which has been reported as 49% in Hispanics, 23% in those of European 
ancestry, and 17% in African Americans [32]. Individuals with rs58542926 TM6SF2 poly-
morphism have shown to possess a greater risk of developing NAFLD (OR 2.13 (95% CI: 
1.36–3.30)) [33]. Another GWAS conducted by Yuan et al. in three populations (total n = 7715) 
with replication in three additional cohorts (total n = 4704) analyzed genetic variations affect-
ing plasma liver enzyme levels and reported six loci that have an effect on plasma levels of 
liver enzymes as well as confirming previously stated associations between the GGT1 locus 
and gamma glutamyl transpeptidase (GGT) levels and between the ABO locus and alkaline 
phosphatase levels [23].
Candidate genes Cohort (n = Population size) Reference
GGT1 and ABO n = 7715; replication in 4704 [23]
PNPLA3 n = 11,340 [24–26]
FDFT1 and COL13A1 n = 236 [27]
PNPLA3, NCAN, PPP1R3B, CCKR, and LYPLAL1 n = 7126; replication in 592 cases and 1405 
control
[28]
PNPLA3, TRIB1, CPN1, loci near HSD17B13, and 
MAPK10
61,089 [29]
PNPLA3 and TM6SF2 2736 [30]
GGT1, gamma-glutamyltransferase 1; PNPLA3, patatin-like phospholipase domain containing 3; FDFT1, farnesyl-
diphosphate farnesyltransferase 1; COL13A1, collagen type XIII alpha 1 chain; NCAN, neurocan; PPP1R3B, protein 
phosphatase 1 regulatory subunit 3B; CCKR, cholecystokinin receptor; LYPLAL1, lysophospholipase-like 1; TRIB1, 
tribbles pseudokinase 1; CPN1, carboxypeptidase N subunit 1; HSD17B13, hydroxysteroid 17-beta dehydrogenase 13; 
MAPK10, mitogen-activated protein kinase 10; TM6SF2, transmembrane 6 superfamily member 2.
Table 1. GWA studies of NAFLD.
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Altogether, this numerous genomic studies propose the association of several genetic factors, 
especially those responsible for lipid metabolism, with NAFLD development. Still, further 
studies are required to deeply understand the effect of genetic variations on the pathogenesis 
of NAFLD to develop specific therapies that prevent the progression of the disease or specific 
treatments at each progressive step of the disease.
3. Transcriptomics in NALFD
The development of transcriptomic tools, predominantly real-time quantitative reverse tran-
scription polymerase chain reaction (qRT-PCR) and microarrays, accompanied by supporting 
informatics and statistical methodologies enables researchers to investigate alterations in global 
mRNA levels in NAFLD. As in many other diseases, besides genetic factors, epigenetic and tran-
scriptomic changes participate the progression of NAFLD. The term epigenetics is described as 
heritable alterations in gene expression patterns that are not encoded directly within DNA but 
are instead determined by related factors such as DNA methylation or histone modifications. 
While these epigenetic changes are heritable, they can also be modified in response to environ-
mental effects [34]. The liver, being the key metabolic organ, is subjected to nutrition-derived 
factors that can alter its epigenetic signature. Two essential factors that play a role in epigen-
etic modifications of histones and DNA are acetyl-CoA and S-adenosylmethionine which are 
also directly involved in glucose or methionine metabolism, respectively [35]. Consequently, 
histone acetylation has been shown to participate to NAFLD development by triggering lip-
ogenic and glycolytic genes, while abnormalities in S-adenosylmethionine levels have been 
demonstrated to result in lipogenesis, accumulation of hepatic triglycerides, and NAFLD [35]. 
In terms of ease in clinical applications, it is better for an epigenetic biomarker to be discovered 
in peripheral blood [36]. Hereof, a promising study that examined body mass index loss in 
obese adolescents reported significance of altered DNA methylation in Aquaporin-9 (AQP9), 
dual specificity protein phosphatase 22 (DUSP22), homeodomain-interacting protein kinase 3 
(HIPK3), troponin T1 (TNNT1), and troponin I3 (TNNI3) genes [37].
MicroRNAs (miRNAs) which are short RNA molecules of about 22 nucleotides that control 
mRNA stability and thus transcription levels are crucial transcriptomic factors that can affect 
NAFLD development [14]. Studies have inconsistent results for their involvement in steato-
sis, possibly due to the variances of diagnostic methods, staging, and miRNA measurement 
[38]. The direct analysis of miRNA in the blood makes them ideal biomarkers for the distinct 
stages of steatosis. Recently, specific microarrays, such as muParaflo microRNA microarrays, 
greatly contributed to the examination of microRNAs in NAFLD. For instance, the expression 
miRNA-122, which constitutes 70% of the total liver miRNAs, has been shown to be aug-
mented in the blood of NAFLD patients [39, 40]. The study of Cermelli et al. that compares 
miRNA levels of NALFD patients and healthy controls reported increased miRNA-34a and 
miRNA-16 levels in NAFLD patients. Also, they suggested that miRNA-122 and miRNA-34a 
might be a useful biomarker for the evaluation of NAFLD and NASH [39]. Besides miRNA-
122, Pirola et al. reported association of miRNA-192 and miRNA-375 with the severity of the 
disease [40]. Nonetheless, since there is a dynamic and multifactorial relationship between 
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miRNAs and gene regulation, further studies and careful evaluations are required before 
miRNAs can be used as biomarkers in the diagnosis and staging of NAFLD.
In addition to epigenetic factors and miRNAs, alterations in gene expression profile also affect 
progression to NAFLD. Several cross-sectional studies performed on cohorts with various 
histological parameters (alcoholic steatohepatitis and NASH vs. no NASH, NASH vs. no 
NASH, control vs. steatosis vs. NASH, control vs. steatosis vs. NASH with steatosis >5% vs. 
NASH with steatosis <5%) reported the significant effect of Wnt pathway as a protagonist, 
besides genes participated in absorption, distribution, metabolism, and excretion (ADME); 
aldose reductase AKR1B10; and keratin family member KRT23 [41–45]. Studies also revealed 
that genes involved in cellular proliferation and ECM organization, such as dermatopontin 
(DPT), were differentially expressed in the liver transcriptome of NAFLD patients [46–48]. 
Unfortunately, subtle alterations in individual’s gene expression caused by interindividual 
heterogeneity of the disease and the adaptive nature of the pathological response limit clear-
cut identification of patient categories and therefore complicate identification of transcrip-
tomic biomarkers [41, 43, 45, 48].
4. Proteomics in NAFLD
The improvement of novel proteomic tools accelerated researches in NAFLD diagnosis and 
discovery of biomarkers. The first study that examined serum protein profiles in NAFLD 
by surface-enhanced laser desorption ionization time of flight mass spectrometry (SELDI-
TOF MS) on 98 obese patients, with 91 NAFLD patients (12 steatosis alone, 52 steatosis 
with non-specific inflammation, 27 NASH) and 7 patients without NAFLD as obese con-
trol, reported 12 significant protein peaks. However, because of the inherent limitation of 
low mass accuracy in SELDI-TOF MS, researchers could only identify fibrinogen γ and 
proposed a possible association with fibrosis [49]. The study of Bell et al. identified sig-
nificant alterations in 55 proteins between NAFLD and NASH with advanced fibrosis by 
performing an ion-intensity-based, label-free quantitative proteomic approach (LFQP) [50]. 
They also reported significant changes of 15 proteins between early NASH and NASH with 
progressed fibrosis. From their data, a 6-protein diagnostic method that includes fibrino-
gen β chain, retinol-binding protein 4, serum amyloid P component, lumican, transgelin 
2, and CD5 antigen-like and a 3-protein diagnostic method consisting of component C7, 
insulin-like growth factor acid labile subunit, and transgelin 2 were developed to diagnose 
the progressive stages of NAFLD (AUROC ranging from 0.83 to 0.91). Moreover, they also 
presented that alanine aminotransferase (ALT) was a low-grade diagnostic protein for the 
evaluation of different stages of NAFLD (AUROC = 0.53) [50]. Several other studies were 
also consistent with the fact that ALT is not a suitable NAFLD diagnosis biomarker, and no 
optimal ALT levels are present to evaluate advanced fibrosis [51]. Even with the inability to 
discover unique biomarkers that could distinguish between NAFLD and NASH, the study 
of Bell et al. greatly contributed into the understanding of the pathogenesis of NAFLD and 
NASH [50]. Generally, most of the proteins identified by several proteomic studies suggest 
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the association of immune system regulation, inflammation, hepatic ECM structure, and 
protein carriers in the blood with NAFLD (Table 2). Nonetheless, even proteomics is a great 
tool for gaining deep insight on the pathogenesis and progression of the disease; unfortu-
nately, these tools cannot yet offer specific biomarkers with major clinical value to diagnose 
NASH or discriminate NASH and steatosis.
5. Conclusions
In conclusion, the Omics studies explained throughout the review supported the fact that 
NAFLD is a complex disease caused by several phenomena such as accumulation and traf-
fic of various lipids in the liver and triggered inflammation responses. Altogether genomic, 
transcriptomic, and proteomic studies are in accordance with the basic detectable pathogenic 
mechanisms of NAFLD which are mitochondrial energetic and structural abnormalities, trig-
gered inflammatory response via multiple targets, and lipotoxicity.
Protein categories Protein markers Reference
Protein carrier Apolipoproteins [52]
CD5 molecule-like (CD5L) [53]
Metabolic pathways Carbamoyl phosphate synthetase I (CPS1) [54]
Glucose-regulated protein 78 (GRP78) [54]
Uric acid [55]
Acute phase protein High sensitive C-reactive protein (Hs-CRP) [56]
Hemoglobin [57]
Serum fucosylated haptoglobin (Fuc-Hpt) [58]
Pentraxin 3 (PTX-3) [59]
Anti-inflammatory and 
antioxidant
Bilirubin [60]
Extracellular matrix Hyaluronic acid [61]
Type IV collagen 7S [62]
Laminin [63]
Lumican [64]
Matrix metallopeptidase 9 (MMP-9) [65, 66]
Immune cells and cytokines C─C motif chemokine ligand 2 (CCL2) and Monocyte 
chemotactic protein 1(MCP1)
[67]
Retinol-binding protein 4 (RBP4) [50, 68–70]
Table 2. Proteomic studies of NAFLD.
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Advances in genomic and transcriptomic tools allow researchers to inspect significant genetic 
polymorphisms and epigenetic alterations, along with miRNA levels in different stages of the 
NAFLD progression. Noticeably, individuals with unfavorable genetic polymorphisms coupled 
with disadvantageous biological environment carry a high risk of developing NAFLD. Moreover, 
development of novel proteomic methodologies also supported the biomarker studies in 
NAFLD which aim to discover key protein molecules that carry significant clinical importance 
in the concourse of the disease. Even though a few candidate serum protein markers achieve to 
distinguish NAFLD and NASH, further validation studies of these biomarkers in larger cohorts 
are still required before they can be clinically used in the diagnosis and evaluation of the disease 
progression. Overall, further advancement of Omics studies is still required to deeply under-
stand the pathophysiology of NAFLD and discover specific biomarkers for clinical use.
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